Table 1 Clinical trials with chemotherapeutic agents causing replication stress used in ovarian cancer treatment. [clinicaltrials.gov] *not applicable
Target | Name of drug/drugs | Objective of trial | Clinical trial phase | Clinical trial identifier |
|---|---|---|---|---|
PARP | BMN 673 (talazoparib) | Patients with deleterious BRCA 1/2 mutation-associated ovarian cancer who have had prior PARP inhibitor treatment | 2 | NCT02326844 |
PARP | BSI-201 (iniparib) Carboplatin/ gemcitabine | Patients with platinum-resistant recurrent ovarian cancer | 2 | NCT01033292 |
PARP | AZD2281 (olaparib) | Study to assess the efficacy and safety of a PARP inhibitor for the treatment of BRCA-positive advanced ovarian cancer | 2 | NCT00494442 |
PARP | Cediranib Olaparib | Patients with ovarian cancer whose cancer worsened despite previously receiving a PARP inhibitor (such as olaparib) | –* | NCT02681237 |
PARP | Rucaparib Nivolumab | Treatment following response to frontline treatment in newly diagnosed ovarian cancer patient | 3 | NCT03522246 |
ATR PARP | AZD6738 Olaparib | ATARI trial test: ATR inhibitor drug AZD6738 and a PARP inhibitor drug olaparib in patients with relapsed gynaecological cancers with an abnormality in ARID1A gene | 2 | NCT04065269 |
WEE1 | MK-1775 Carboplatin | Patients with p53 mutated epithelial ovarian cancer that have been treated with first line treatment (paclitaxel–carboplatin combination therapy) and that have shown early relapse (within 3 months) | 2 | NCT01164995 |
ATR PARP | AZD6738 Olaparib | Combination ATR and PARP inhibitor (CAPRI) trial with AZD 6738 and olaparib in recurrent ovarian cancer | 2 | NCT03462342 |
ATR | AZD6738 Paclitaxel | Refractory cancer patients who have failed to standard-of-care chemotherapy | 1 | NCT02630199 |
ATR | M6620 Avelumab Carboplatin | In participants with PARPi-resistant, recurrent, platinum-sensitive ovarian, primary peritoneal or fallopian tube cancer | 2 | NCT03704467 |
ATR | M6620 Gemcitabine | Patients with recurrent ovarian, primary peritoneal or fallopian tube cancer | 2 | NCT02595892 |
ATR | M6620 Topotecan | In small cell cancers and extrapulmonary small cell cancers | 2 | NCT02487095 |
ATR | M6620 Carboplatin, gemcitabine | Adult women with platinum-sensitive, recurrent high-grade serous or high-grade endometrioid ovarian, primary peritoneal or fallopian tube cancer | 2 | NCT02627443 |
ATR | M6620 Avelumab Nedisertib | DDR-deficient metastatic or unresectable solid tumors | 1 | NCT04266912 |
ATR | M6620 Carboplatin Gemcitabine | Patients with recurrent and metastatic ovarian, primary peritoneal or fallopian tube cancer | 2 | NCT02627443 |
ATR | BAY 1895344 | Patients with advanced solid tumors and lymphomas | 1 | NCT03188965 |
ATR PARP | BAY 1895344 Niraparib | Advanced solid tumors and ovarian cancer | 1 | NCT04267939 |
ATR | VX-803 (M4344) | Women with recurrent ovarian cancer that has progressed while on a PARP inhibitor | 1 | NCT02278250 |
ATR PARP | VX-803 (M4344) Niraparib | Women with recurrent ovarian cancer that has progressed while on a PARP inhibitor | 1 | NCT04149145 |
ATR PARP | AZD 6738 Olaparib | HR-deficient patients with/without additional mutations in ATM, CHK-2, MRN (MRE11/NBS1/RAD50), CDKN2A/B and APOBEC | 2 | NCT02576444 |
CHK1 PARP | Prexasertib (LY2606368) Olaparib | Solid tumors | 1 | NCT03057145 |
CHK1 | Prexasertib (LY2606368) | BRCA1/2 mutation-associated breast or ovarian cancer, triple negative breast cancer and HGSOC | 2 | NCT02203513 |
CHK1 | Prexasertib (LY2606368) | Patients with platinum-resistant or refractory ovarian cancer | 2 | NCT03414047 |